| 2023-03-16 |
1 |
Complaint |
of U.S. Patent
Nos. 8,877,776, 11,091,439, 11,091,440, 11,098,015, and 11,298,349 (the “Patents-in-Suit…BACKGROUND
19. U.S. Patent No. 8,877,776 (“the ’776 Patent”), titled “(L)-malate salt of N… COUNT I: INFRINGEMENT OF U.S. PATENT NO. 8,877,776
33. Exelixis incorporates each…of the ’776 Patent, the ’439 Patent, the ’440 Patent, the
’015 Patent, and the ’349 Patent are not invalid…of the ’776 Patent, the ’439 Patent, the ’440
Patent, the ’015 Patent, and the ’349 Patent, will infringe |
External link to document |
| 2023-05-05 |
13 |
Redacted Document |
alleging infringement of United States Patent Nos. 8,877,776, 11,091,439, 11,091,440,
11,098,015, and…and 11,298,349 (collectively, the “Asserted Patents”) by Cipla’s submission of
Abbreviated New Drug Application…Products”)
before the expiration of the Asserted Patents;
WHEREAS, Exelixis has filed suit against…. No. 22-228-RGA asserting infringement of U.S. Patent
Nos. 11,091,439, 11,091,440, 11,098,015, and 11,298,349…March 2023
4 May 2023
1:23-cv-00287
835 Patent - Abbreviated New Drug Application(ANDA)
None |
External link to document |
